ACTIV-1 infliximab, abatacept and cenicriviroc (CVC) as immunomodulators in COVID-19. Emily Ko
#IDWeek22
COVID-19 with pneumonitis / hypoxia
Primary endpoint - time to recovery
Ages 55, 60% male, BMI 32, 50% obese
Receiving remdesivir and steroids, <10% IMV
#IDWeek22
COVID-19 with pneumonitis / hypoxia
Primary endpoint - time to recovery
Ages 55, 60% male, BMI 32, 50% obese
Receiving remdesivir and steroids, <10% IMV
Infliximab - about 500 in active and placebo arms; no diff in time to recovery. 41% lower odds of day 28 mortality, 32% higher odds of clinical status at day 14.
No diff in adverse events
No diff in adverse events
Abatacept - about 500 in active and placebo; no diff in time to recovery, Reduced odds of day 28 mortality. No diff in adverse events, with slightly higher bacterial infections (not stats sig).
Increasingly apparent that immune modulation important. Consistent with tocilizumab and baricitinib.
Where is the sweet spot for immune modulation? Especially now with mainly vaccinated populations.
Where is the sweet spot for immune modulation? Especially now with mainly vaccinated populations.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
